Enalaprilat and losartan decrease erythroid precursors frequency in cells from patients with polycythemia vera

Figures & data

Figure 1. Clonogenic potential of MNCs from JAK2V617F positive PV patients in medium supplemented with EPO only. CFU obtained from peripheral blood MNCs treated with enalaprilat (A) and losartan (B); n = 3. CFU obtained from bone marrow MNCs treated with enalaprilat (C) and losartan (D); n = 3.

Figure 2. Clonogenic potential of cells isolated from JAK2V617F negative erythrocytosis patients in pan-myeloid differentiation medium. CFU obtained from peripheral blood MNCs treated with enalaprilat (A) and losartan (B), n = 4.

Figure 3. Clonogenic potential of MNCs from JAK2V617F positive PV patients in a medium for pan-myeloid differentiation. CFU obtained from peripheral blood MNCs treated with enalaprilat (A) and losartan (B); n = 13. CFU obtained from bone marrow MNCs treated with enalaprilat (C) and losartan (D); n = 3. Total colony number obtained with both drugs with peripheral blood MNCs (E), n=13; and bone marrow MNCs (F), n = 3.

Figure 4. Clonogenic potential of MNCs from JAK2V617F positive PV patients treated with enalaprilat and losartan for 24-h before plating in a medium for pan-myeloid differentiation. CFU obtained from peripheral blood MNCs treated for 24 hours with enalaprilat (A) and losartan (B); n = 5. CFU obtained from bone marrow MNCs treated for 24 hours with enalaprilat (C) and losartan (D); n = 3. Total colony number obtained with both drugs with peripheral blood MNCs (E), n = 5; and bone marrow MNCs (F), n = 3.

Data availability statement

The data that support the findings of this study are available from the corresponding authors upon reasonable request.